Home LiteratureArticle Details
PMID: 12438586 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes.

Journal of virology ·Vol. 76 ·No. 24 ·2002-12-00 ·Pages 12603-10

Jin X, Gao X, Ramanathan M, Deschenes GR, Nelson GW, O'Brien SJ, Goedert JJ, Ho DD, O'Brien TR, Carrington M

Abstract

Human immunodeficiency virus type 1 (HIV-1)-infected individuals with HLA-B*35 allelic variants B*3502/3503/3504/5301 (B*35-Px) progress more rapidly to AIDS than do those with B*3501 (B*35-PY). The mechanisms responsible for this phenomenon are not clear. To examine whether cellular immune responses may differ according to HLA-B*35 genotype, we quantified HIV-1-specific CD8(+)-T-cell (CTL) responses using an intracellular cytokine-staining assay with specimens from 32 HIV-1-positive individuals who have B*35 alleles. Among them, 75% had CTL responses to Pol, 69% had CTL responses to Gag, 50% had CTL responses to Nef, and 41% had CTL responses to Env. The overall magnitude of CTL responses did not differ between patients bearing B*35-Px genotypes and those bearing B*35-PY genotypes. A higher percentage of Gag-specific CTL was associated with lower HIV-1 RNA levels (P = 0.009) in individuals with B*35-PY. A negative association between CTL activity for each of the four HIV antigens and viral load was observed among individuals with B*35-PY, and the association reached significance for Gag. No significant relationship between CTL activity and viral load was observed in the B*35-Px group. The relationship between total CTL activity and HIV RNA among B*35-Px carriers differed significantly from that among B*35-PY carriers (P < 0.05). The data are consistent with the hypothesis that higher levels of virus-specific CTL contribute to protection against HIV disease progression in infected individuals with B*35-PY, but not in those with B*35-Px.

MeSH Terms
Acquired Immunodeficiency Syndrome/immunology,virology Disease Progression Genotype HIV-1/immunology HLA-B35 Antigen/genetics Humans T-Lymphocytes, Cytotoxic/immunology Viral Load
Chemicals
HLA-B35 Antigen
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Jin Xia
Infectious Disease Unit, University of Rochester Medical Center, 601 Elmwood Avenue, Box 689, Rochester, NY 14642, USA. [email protected]
Gao Xiaojiang
Ramanathan Murugappan
Deschenes Geoffrey R
Nelson George W
O'Brien Stephen J
Goedert James J
Ho David D
O'Brien Thomas R
Carrington Mary
References (39)
39 references, click to expand
  1. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
    Nature. 2000 Sep 21;407(6802):386-90 PMID: 11014195
  2. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.
    AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1219-28 PMID: 10480635
  3. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects.
    J Clin Invest. 2001 May;107(10):1303-10 PMID: 11375420
  4. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.
    J Virol. 2001 Sep;75(18):8681-9 PMID: 11507213
  5. Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion.
    J Infect Dis. 2001 Dec 1;184(11):1465-9 PMID: 11709791
  6. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy.
    J Virol. 2002 Mar;76(5):2206-16 PMID: 11836398
  7. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.
    J Virol. 2002 Mar;76(5):2298-305 PMID: 11836408
  8. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
    Nat Rev Immunol. 2002 Apr;2(4):283-91 PMID: 12001999
  9. The influence of HLA genotype on AIDS.
    Annu Rev Med. 2003;54:535-51 PMID: 12525683
  10. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases.
    MMWR Morb Mortal Wkly Rep. 1987 Aug 14;36 Suppl 1:1S-15S PMID: 3039334
  11. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.
    Nature. 1991 Dec 12;354(6353):453-9 PMID: 1721107
  12. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
    MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 PMID: 1361652
  13. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.
    J Exp Med. 1993 Feb 1;177(2):249-56 PMID: 8093890
  14. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  15. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.
    J Exp Med. 1995 Apr 1;181(4):1365-72 PMID: 7699324
  16. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors.
    J Virol. 1995 Sep;69(9):5838-42 PMID: 7637030
  17. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.
    Nat Med. 1995 Apr;1(4):330-6 PMID: 7585062
  18. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques.
    Nat Med. 1995 Nov;1(11):1167-73 PMID: 7584989
  19. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.
    Nat Med. 1999 Nov;5(11):1270-6 PMID: 10545993
  20. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.
    Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14 PMID: 10694578
  21. CD8+ T cell effector mechanisms in resistance to infection.
    Annu Rev Immunol. 2000;18:275-308 PMID: 10837060
  22. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection.
    Nat Med. 1996 Apr;2(4):405-11 PMID: 8597949
  23. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.
    J Exp Med. 2000 Jul 3;192(1):63-75 PMID: 10880527
  24. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors.
    J Immunol. 2000 Jul 15;165(2):1082-92 PMID: 10878387
  25. Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype.
    J Virol. 2000 Oct;74(19):9144-51 PMID: 10982361
  26. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.
    Science. 1996 Apr 26;272(5261):537-42 PMID: 8614801
  27. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.
    JAMA. 1996 Jul 10;276(2):105-10 PMID: 8656501
  28. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo.
    J Immunol. 1996 Nov 1;157(9):4212-21 PMID: 8892659
  29. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection.
    AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1691-8 PMID: 8959245
  30. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
    Nat Med. 1997 Feb;3(2):205-11 PMID: 9018240
  31. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.
    Nat Med. 1997 Feb;3(2):212-7 PMID: 9018241
  32. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo.
    J Infect Dis. 1997 Jul;176(1):118-25 PMID: 9207357
  33. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.
    J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8 PMID: 9266987
  34. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
    N Engl J Med. 1997 Oct 30;337(18):1267-74 PMID: 9345075
  35. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
  36. Longitudinal HIV-1 RNA levels in a cohort of homosexual men.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jun 1;18(2):155-61 PMID: 9637580
  37. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
    Science. 1999 Mar 12;283(5408):1748-52 PMID: 10073943
  38. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
    Nat Med. 1999 Jun;5(6):677-85 PMID: 10371507
  39. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.
    N Engl J Med. 2001 May 31;344(22):1668-75 PMID: 11386265
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2002-12-00
Pages
12603-10
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC136673
Subset
IM
Grants
NCI NIH HHS · N01CO12400 · United States
NCI NIH HHS · N01 CO 12400 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]